Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN.
Authors
Luhua Wang
Cancer Hospital of Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
Luhua Wang , Ming Chen , Ken Kato , Lucjan Wyrwicz , Elizabeth Catherine Smyth , Anastasia Jiang , Di Zhang , Scott H. Robbins , Philip He , Alejandra Negro , Nabil F. Saba
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04550260
DOI
10.1200/JCO.2022.40.4_suppl.TPS373
Abstract #
TPS373
Poster Bd #
M6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.
First Author: Karyn A. Goodman
Poster
2022 ASCO Annual Meeting
KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.
First Author: Hope S. Rugo
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2021 Gastrointestinal Cancers Symposium
CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
First Author: Jin Li